4 September 2026 0 Comments Gregory Ashwell

Paragraph IV Explained: How Generic Drugs Challenge Patents

Discover how Paragraph IV certification enables generic drugs to challenge brand-name patents under the Hatch-Waxman Act. Learn about the 30-month stay, 180-day exclusivity rewards, and the legal strategies shaping pharmaceutical competition.